openPR Logo
Press release

Registration opens for SMi’s 4th Annual Ophthalmic Drugs Conference

06-25-2020 04:49 PM CET | Health & Medicine

Press release from: SMi Group

Registration opens for SMi’s 4th Annual Ophthalmic Drugs

SMi reports: Registration is now open for the 4th annual Ophthalmic Drugs Conference, taking place in London on the 23rd-24th November 2020.

SMi presents the 4th Annual Ophthalmic Drugs Conference taking place on the 23rd-24th of November 2020, in London.

The global ophthalmic drug market is forecast to surpass $60 billion USD by 2025 with increasing focus from the industry on alternative delivery approaches and improving the effectiveness of the current repertoire of drugs in order to grow away from intravitreal injections and other surgical approaches to ocular therapy. With 50% of the global population predicted to have complications in their sight within the next few decades, ophthalmic medicine is set to become one of the biggest industries in pharmaceuticals.

The newly-released brochure with the three-day agenda and full speaker line-up is available to download online at www.ophthalmicdrugs.com/pr1openpr

As Europe’s leading Ophthalmic Drugs conference, the conference will explore new discoveries in the treatment of ocular disease, innovations in combination technologies, and the utterly unique challenges that are faced in the treatment of one of the most complex organs in the body.

Chair For 2020:

• Mitchell de Long, Vice President, Chemistry, Aerie Pharmaceuticals

Featured 2020 Speakers Include:

• Magali Taiel, Chief Medical Officer, Gensight-Biologics
• Alan Franklin, CEO, Forward Vue Pharma
• Brian Levy, CEO, Ocunexus Therapeutics
• Victor Chong, Global Medical Head, Retinal Health, Boehringer Ingelheim International GmbH
• Harminder Dua, Chair and Professor of Ophthalmology, University of Nottingham
• Ian Catchpole, Chief Scientific Officer, Horama
• Francine Behar-Cohen, Chief Innovation Officer, Eyevensys
• Dr Thakur Raghu Raj Singh, Reader in Pharmaceutics, Queen’s University Belfast

Highlights For 2020:
• INSIGHT into the newest techniques in ocular drug design and delivery
• EXPLORE the impacts and applications of controlled release technologies
• LEARN how advanced medical devices are changing the face of combined therapy
• UNDERSTAND the latest developments in overcoming the challenge of treating such a complex organs

This two-day agenda will offer peer-to-peer networking opportunities with leaders in the ophthalmic sphere, from Heads of Drug Development and Senior Directors of Ophthalmology, all the way to academic forerunners in the research into ocular therapy

Registration is now open for interested parties at www.ophthalmicdrugs.com/pr1openpr

Ophthalmic Drugs Conference
23rd-24th November 2020
Holiday Inn Kensington High Street, London, UK
#OphthalmicDrugs
For exclusive tailored sponsorship/table-top opportunities contact: Alia Malick on +44 (0)20 7827 6168 or email amalick@smi-online.co.uk
For media queries please contact Jinna Sidhu at hsidhu@smi-online.co.uk or call +44 (0)20 7827 6088

---End---

Ground Floor, India House, 45 Curlew Street
London, SE1 2ND
Jinna Sidhu

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Registration opens for SMi’s 4th Annual Ophthalmic Drugs Conference here

News-ID: 2080455 • Views: 410

More Releases from SMi Group

Sponsor Boeing Presentation Released for the Virtual Military Airlift and Air-to …
SMi Group Reports: Senior representatives from Boeing are set to give a joint presentation at the Military Airlift and Air-to-Air Refuelling Conference in December Delegates at this year’s Military Airlift and Air-to-Air Refuelling Conference, taking place virtually on the 1st-2nd December 2020, will have the opportunity to schedule meetings with sponsors and visit sponsor exhibition stands throughout the day. All attendance by military and government personnel will be free of charge
Exclusive interview released with CJOS COE ahead of the virtual Maritime Reconna …
SMi Group reports: A senior representative from the Combined Joint Operations from the Sea Centre of Excellence (CJOS COE) is speaking at the virtual event next February. Ahead of SMi Group’s Maritime Reconnaissance and Surveillance Technology conference, taking place virtually on the 3rd and 4th February 2021, a speaker interview has been released with Commodore Thomas Guy, Deputy Director, CJOS COE to discuss his role, current priorities, opportunities and the
Border Security 2021 turns into a Virtual Conference
SMi Group reports: The Border Security conference taking place next February will no longer take place in Prague and will now be a virtual event. In light of on-going developments with COVID-19, SMi Group have decided to move its 14th annual Border Security conference, taking place on the 10th-11th February 2021, to a fully online, virtual experience. SMi Group’s virtual conference platform will enable attendees to: • Create their own virtual profile • Connect with
Boeing sign up to sponsor the Virtual Military Airlift and Air-to-Air Refuelling …
SMi Group Reports: Boeing is the latest sponsor to confirm their attendance at the Military Airlift and Air-to-Air Refuelling Conference in December SMi Group are delighted to announce Boeing have now signed up to sponsor, speak and exhibit at the virtual 21st Annual Military Airlift and Air-to-Air Refuelling Conference, taking place on the 1st-2nd December 2020. Boeing is the world's largest aerospace company and leading manufacturer of defense, space and security

All 5 Releases


More Releases for Drug

Biologics Drug Discovery Market
2019-2025 Biologics Drug Discovery Market Report with Depth Analysis The biologics drug discovery involves target identification, hit-to-lead stage, lead identification and optimization. The report presents a comprehensive overview, market size, shares, and growth opportunities of Biologics Drug Discovery market by product type, application, key manufacturers and key regions. Request For Free report Sample -https://www.reportsmonitor.com/request_sample/306320 Scope of the Report: Furthermore, Biologics Drug Discovery Market report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers or
Opioid Antagonist Drug Market
The global market has been prognosticated to earn demand from popular types of products such as external use, oral and applications such as household and hospital. The Company has made available another publication in its Healthcare archive of market intelligence reports, which is titled “Global Opioid Antagonist Drug Market Research Report 2018.” While the threat of substitutes and technological risks could have an unfavorable impact on the global market, potential
Drug and cosmetics
Drug and Cosmetics Conferences regards each one of the individuals to go to the On “Drug and Cosmetics” amidst October 17-October 18, 2018 in Toronto, Canada which melds brief keynote presentations, speaker talks, Exhibition, Symposia, Workshops. Drug and Cosmetics Congress is one of the meetings and conferences which will be visited by all the prestigious cosmetologists, Scientists, fiery inspectors, postgraduates, affiliations, business meanders under a solitary rooftop. DRug and cosmetics BLESSY MATHEW Program
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning